Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omi...
https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm?s_cid=mm7107e2_w
https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm?s_cid=mm7107e2_w
Jan 1st, 2022 - This report describes how vaccine effectiveness against COVID-19–associated emergency department/urgent care visits and hospitalizations was higher after the third dose but decreased with time.
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One...
https://www.cdc.gov/mmwr/volumes/71/wr/mm7106e2.htm?s_cid=mm7106e2_w
https://www.cdc.gov/mmwr/volumes/71/wr/mm7106e2.htm?s_cid=mm7106e2_w
Jan 1st, 2022 - This report describes how COVID-19 vaccinations and booster doses were associated with lower chances of ICU admission for hospitalized SARS-CoV-2 infected adults during Omicron predominance.
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One...
https://www.cdc.gov/mmwr/volumes/71/wr/mm7106e2.htm?s_cid=mm7106e2_x
https://www.cdc.gov/mmwr/volumes/71/wr/mm7106e2.htm?s_cid=mm7106e2_x
Jan 1st, 2022 - This report describes how COVID-19 vaccinations and booster doses were associated with lower chances of ICU admission for hospitalized SARS-CoV-2 infected adults during Omicron predominance.
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United S...
https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm?s_cid=mm7038e1_w
https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm?s_cid=mm7038e1_w
Jan 1st, 2021 - This report describes COVID-19 vaccine effectiveness against hospitalizations for all three vaccines, with Moderna as the most effective against hospitalization.
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a7.htm?s_cid=mm7037a7_w
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a7.htm?s_cid=mm7037a7_w
Jan 1st, 2021 - COVID-19 vaccine effectiveness against hospitalizations was stable, but it declined against new infections among adults in New York during May–July 2021.
Correction and Republication: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a6.htm?s_cid=mm7037a6_w
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a6.htm?s_cid=mm7037a6_w
Jan 1st, 2021 - This report describes a correction to a previously published report in MMWR.
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United S...
https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm?s_cid=mm7038e1_x
https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm?s_cid=mm7038e1_x
Jan 1st, 2021 - This report describes COVID-19 vaccine effectiveness against hospitalizations for all three vaccines, with Moderna as the most effective against hospitalization.
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a7.htm?s_cid=mm7037a7_x
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a7.htm?s_cid=mm7037a7_x
Jan 1st, 2021 - COVID-19 vaccine effectiveness against hospitalizations was stable, but it declined against new infections among adults in New York during May–July 2021.
Correction and Republication: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a6.htm?s_cid=mm7037a6_x
https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a6.htm?s_cid=mm7037a6_x
Jan 1st, 2021 - This report describes a correction to a previously published report in MMWR.
Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020
https://WWW.CDC.GOV/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w
https://WWW.CDC.GOV/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w
Jan 1st, 2020 - This report describes data findings for hospitalized and nonhospitalized COVID-19 patients from six metropolitan Atlanta, Georgia, hospitals and associated outpatient clinics.
Notes from the Field: Candida auris and Carbapenemase-Producing Organism Prevalence in a Pediatric Hospital Providing Long-Term Transitional Care — Chicago, Illinois, 2019
https://WWW.CDC.GOV/mmwr/volumes/69/wr/mm6934a5.htm?s_cid=mm6934a5_w
https://WWW.CDC.GOV/mmwr/volumes/69/wr/mm6934a5.htm?s_cid=mm6934a5_w
Jan 1st, 2020 - This report describes the prevalence of the emerging fungal pathogen Candida auris in a Chicago pediatric hospital that provides long-term care.
QuickStats: Percentage of Deaths, by Place of Death — National Vital Statistics System, United States, 2000–2018
https://WWW.CDC.GOV/mmwr/volumes/69/wr/mm6919a4.htm?s_cid=mm6919a4_w
https://WWW.CDC.GOV/mmwr/volumes/69/wr/mm6919a4.htm?s_cid=mm6919a4_w
Jan 1st, 2020 - The percentage of deaths from all causes that occurred in a hospital decreased from 48.0% in 2000 to 35.1% in 2018.
Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020
https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_x
https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_x
Jan 1st, 2020 - This report describes data findings for hospitalized and nonhospitalized COVID-19 patients from six metropolitan Atlanta, Georgia, hospitals and associated outpatient clinics.
Notes from the Field: Candida auris and Carbapenemase-Producing Organism Prevalence in a Pediatric Hospital Providing Long-Term Transitional Care — Chicago, Illinois, 2019
https://www.cdc.gov/mmwr/volumes/69/wr/mm6934a5.htm?s_cid=mm6934a5_w
https://www.cdc.gov/mmwr/volumes/69/wr/mm6934a5.htm?s_cid=mm6934a5_w
Jan 1st, 2020 - This report describes the prevalence of the emerging fungal pathogen Candida auris in a Chicago pediatric hospital that provides long-term care.
QuickStats: Percentage of Deaths, by Place of Death — National Vital Statistics System, United States, 2000–2018
https://www.cdc.gov/mmwr/volumes/69/wr/mm6919a4.htm?s_cid=mm6919a4_w
https://www.cdc.gov/mmwr/volumes/69/wr/mm6919a4.htm?s_cid=mm6919a4_w
Jan 1st, 2020 - The percentage of deaths from all causes that occurred in a hospital decreased from 48.0% in 2000 to 35.1% in 2018.
Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020
https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w
https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w
Jan 1st, 2020 - This report describes data findings for hospitalized and nonhospitalized COVID-19 patients from six metropolitan Atlanta, Georgia, hospitals and associated outpatient clinics.
Readmissions after hospital care for meningitis in the United States.
https://doi.org/10.1016/j.ajic.2019.10.025
American Journal of Infection Control; Ellis DE, Zaoutis T et. al.
https://doi.org/10.1016/j.ajic.2019.10.025
American Journal of Infection Control; Ellis DE, Zaoutis T et. al.
Dec 22nd, 2019 - Our objectives were to (1) characterize patient and clinical characteristics of adults hospitalized with meningitis; (2) describe meningitis hospitalization outcomes, including 30- and 90-day readmissions; and (3) determine whether clinical, patient, or index hospitalization characteristics are associated with readmission and readmission outcomes. This retrospective study of the 2014 National R...
BP Control More Important in ICH Patients on Antithrombotics
https://emedicine.medscape.com/viewarticle/825206
https://emedicine.medscape.com/viewarticle/825206
NICE, France — Latest results from a combined analysis of the INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial) 1 and 2 studies in patients with intracerebral hemorrhage (ICH) show that early intensive blood pressure lowering results in a reduced absolute growth of hematoma, and this effect was greater in patients who had previously received antithrombotics. "Earl...
Too Much Exercise: Studies Report J-Shaped Link Between Exercise and CVD Risks
https://emedicine.medscape.com/viewarticle/825266
https://emedicine.medscape.com/viewarticle/825266
HEIDELBERG, GERMANY and STOCKHOLM, SWEDEN — Two new studies published this week lend credence to the idea that when it comes to exercise, there apparently can be too much of a good thing. In the first study, led by Dr Nikola Drca (Karolinska University Hospital, Stockholm, Sweden) and published online May 14, 2014 in Heart, investigators report that men who exercised for more than five hours pe...
Tissue More Important Than Time for tPA Treatment in Stroke?
https://emedicine.medscape.com/viewarticle/825271
https://emedicine.medscape.com/viewarticle/825271
NICE, France — Treating patients with thrombolysis should not be based purely on time, and a stronger predictor of who will benefit most is the amount of dead tissue in the brain as visible on contrast computed tomography (CT), a new registry study suggests. The study was presented at the XXIII European Stroke Conference (ESC) by Andrew Bivard, PhD, imaging scientist at Newcastle University, Jo...
